Bortezomib

Data Sheet For research use only. Not for human use.

Cat. No. ：BCP01781CAS No. ：179324-69-7Purity：98%

Get Quotation Now

Tel: 0086-13026320035 or orders@biochempartner.com

* Required Fields.

Please complete the form below and you will get the price list in 1 minute.

* Required Fields.

Please complete the form below and we will contact you shortly.

* Required Fields.

Please complete the form below and we will contact you shortly.

CAS No.	179324-69-7	Cat. No.	BCP01781
Name	Bortezomib
Synonyms	PS-341;PS341;PS 341; LDP 341; LDP-341 ;LDP341; MLN341; MLN-341; MLN 341;
SMILES	B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
Chemical Name
Formula	C19H25BN4O4	M. Wt	384.24
Purity	98%	Storage	Store at 4-8°C
Description	Bortezomib is a dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.